Subject Index

N-Acetylaspartate (NAA), 442
Action potential (AP), chronic cocaine in hippocampus and, 84
Activator protein-1 (AP-1)
  binding activities of, 13
  definition of, 4
Adrenal system, *d*-AMP and, 148
Alcoholism, 410
Allometric relationship, growth phase, 260
Amines, SERT and, 250
AMP (*see* Amphetamine)
Amphetamine (AMP)
  non-aminergic effects of, 327
  prenatal exposure to, 256
d-Amphetamine (*d*-AMP)
  adrenal system and, 148
  stress and, 148
Amphetamine psychosis, 367
Anxiety, cocaine and, 80
AP (*see* Action potential)
AP-1 (*see* Activator protein-1)
L-Arginine-NO pathway, METH-induced toxicity and, 178
Astrogliosis, ibogaine and, 205

Behavioral sensitization
  brain histaminergic neuron system and, 353
  dopamine level at nucleus accumbens and, 367
  G protein subclass mRNAs and, 110
  METH and, 13
  [^{11}C]methamphetamine and, 401
  repeated intermittent administration of amphetamine and, 310
  rolipram and, 379
Beta-tubulin, ibogaine and, 207
Biodisposition, species differences and, 128
Bioelectrical properties of hippocampal neurons, cocaine and, 81

C57BL/6J mouse, *d*-AMP and, 151
c-Fos, immediate early gene and, 5
c-fos immunocytochemistry, 229
c-Jun, Fras and, 14
Calbindin, Purkinje cell necrosis and, 223
$^{45}Ca^{2+}$ uptake, glutamate-induced, 332
cAMP (*see* Cyclic adenosine monophosphate)
Cardiotoxicity, cocaine and, 77
Casein, ssCRE-BP and, 46
Caudate nucleus
  dopamine concentration in, 396
  dopamine D_2 receptor binding in, 295
CD-1 mouse, *d*-AMP and, 158
Cell viability, 328
Central nervous system (CNS), ibogaine and, 205
Cerebellar nuclei, ibogaine and, 222
Cerebellum, ssCRE-BP and, 42
Cerebral cortex, ssCRE-BP and, 42
Cerebrospinal fluid (CSF), NE and MHPG levels and, 426
p-Chloroamphetamine (pCA)
  serotonin and, 168
  sigma receptor ligands and, 199
Chronic cocaine treatment, 3
Chronic Fras, identifying, 7
Cingulate cortex, AP-1 binding activities in, 14
Cocaine
  dopamine D_1 receptor mutant mice and, 53
  dopamine transporter and, 388
  motor activity and, 76
  novel transcription factors induced by, 1
  nucleus accumbens and, 366
  prenatal exposure to, 256
  seizure activity and, 340
Cocaine action, mechanisms of, 51
Color and position discrimination, gestational cocaine and, 303
Conditioned taste aversion, prenatal cocaine and, 291
Conjunctivitis, 278
Convulsions, cocaine and, 343
CORT (*see* Corticosterone)
Cortico-olivary-cerebellar path, 236
Corticosterone (CORT), thymus and spleen and, 153
CRE (*see* Cyclic adenosine monophosphate response element)
CRE-BP (*see* Cyclic adenosine monophosphate response element binding protein)
Cyclic adenosine monophosphate (cAMP)
  cAMP-dependent protein kinase A and, 2
  striatal, effect of METH and rolipram on, 378
Cyclic adenosine monophosphate response element (CRE), human 14.3.3 η chain gene and, 68

Cyclic adenosine monophosphate response element binding protein (CRE-BP), 14.3.3 η chain gene and, 73

DA (*see* Dopamine)
Development, embryonic, SERT in, 244
Dextromethorphan, 5-HT and 5-HIAA and, 201
3,4-Dihydroxyphenylacetic acid (DOPAC), methamphetamine and, 189
N,N-Dipropyl-2-[4-methoxy-3-(2-phenylethoxy)phenyl]ethylamine monohydrochloride (*see* NE-100)
Dog, PET study of, 402
DOPAC (*see* 3,4-Dihydroxyphenylacetic acid)
Dopamine (DA)
  d-AMP and, 151
  hypersensitivity of nucleus accumbens neurons to, 136
  methamphetamine and, 189
  PCR mimic and, 91
  psychotoxicity and, 368
  striatal, rolipram and, 379
Dopamine (DA) release, toxic dose of METH and, 324
Dopamine D_1 receptor
  AP-1 binding activity and, 15
  cocaine and, 53
  METH-induced increase of extracellular HA and, 355
Dopamine D_2 receptor gene, 409
Dopamine D_2 receptor-mediated neurotransmission, 355
Dopamine neurons, TH mRNA and, 371
Dopamine receptors, binding assays of, 291
Dopamine transporter, COS cells and, 388

Electroencephalographic signals, 394
Epinephrine, plasma, 422
Expert systems, 118
Eye, development of, 274

FEN (*see* Fenfluramine)
Fenfluramine (FEN), serotonin and, 168
d-FEN (*see d*-Fenfluramine)
d-Fenfluramine (*d*-FEN), *d*-AMP neurotoxic properties in common with, 162
Fetal exposure, nonhuman primate animal model of, 301
5-HT (*see* Serotonin)
5′-upstream region, human 14.3.3 η chain gene and, 73
Flashbacks, methamphetamine-induced, 415
Fluorescence *in situ* hybridization (FISH), human 14.3.3 η chain gene and, 72
α-Fluoromethylhistidine, 356
Fluoxetine, maternally administered, 242
Fos-like proteins, AP-1 binding activities and, 13
Fos-related antigens (Fras)
  anti c-Jun antibodies and, 14
  AP-1 and, 5
FosB, Fras and, 7
Fras (*see* Fos-related antigens)
Fura-2 dye, intracellular calcium measured by, 85

Gene expression
  dopamine receptor, 89
  regulation of, 4
Gestational exposure, cocaine, 274
Gi2 α (*see* G protein subclass Gi2)
GIRK channels (*see* G-protein-activated K^+ channels)
Glial fibrillary acidic protein (GFAP), ibogaine and, 205, 224
Gliosis, ibogaine and, 209
Glutamate, methamphetamine neurotoxicity and, 315
Glutamate transporter (GLT-1), rat striatum and, 310
G protein, methamphetamine and, 110
G protein subclass Gi2 α mRNA, 114
G-protein-activated K^+ (GIRK) channels, functional couplings of opioid receptors with, 95
Growth parameters, prefrontal cortex, 256

Hair, drug concentrations in, 302
Haloperidol
  AMP-induced increases in [^{3}H]TCP binding to intact cells and, 331
  dopamine- and methamphetamine-induced inhibition and, 141
  subacute PCP and, 31
Harmaline, ibogaine and, 217
Heart, SERT and, 249
Heart rate, cocaine and, 396
5-HIAA (*see* 5-Hydroxyindoleacetic acid)
High performance liquid chromatography (HPLC), methamphetamine psychosis and, 431
Hippocampus, neurobiological actions of cocaine in, 78

Histamine (HA), brain histaminergic neuron system and, 354
L-Histidine, METH and, 356
Histochemistry
  ibogaine, 220
  NADPH diaphorase, 230
Homovanillic acid (HVA), methamphetamine and, 189
HPLC (*see* High performance liquid chromatography)
Human, retina of, 274
Human 14.3.3 η chain gene, 65
HVA (*see* Homovanillic acid)
5-Hydroxyindoleacetic acid (5-HIAA)
  dextromethorphan and, 201
  methamphetamine and, 193

Ibogaine (IBG), astrogliosis and, 205
Ibogaine dosing, 219
IEGs (*see* Immediate early genes)
Immediate early genes (IEGs)
  regulation of, by cocaine, 5
  subacute PCP and, 33
  transcriptional factors and, 13
Immunohistochemistry, SERT protein and, 247
In situ hybridization
  distribution of mGIRK mRNAs examined by, 100
  mSERT and, 245
In vitro scaling, 124
In vivo scaling, 126
Intracellular calcium, cocaine and, 83
Intravenous drug addiction, 412

Kinetic dynamic predictions, species differences and, 129

Learning, gestational cocaine and, 303
Lidocaine, seizure activity and, 341
Locomotor activity
  d-amphetamine and, 290
  cocaine and, 79
  rolipram and, 380
Long-term potentiation (LTP), cocaine and, 82
LTP (*see* Long-term potentiation)

Magnetic resonance spectroscopy (MRS), white matter changes and, 441
MDA (*see* Methylenedioxyamphetamine)
d-MDA (*see d*-Methylenedioxyamphetamine)
MDMA (*see* 3,4-Methylenedioxymethamphetamine)
d-MDMA (*see d*-3,4-Methylenedioxymethamphetamine)
ME-LI (*see* Methionine enkephalin-like immunoreactivity)
Memory, short-term, 303
Metabolic rate, *in vitro*, 126
Metabolites, ibogaine, 228
METH (*see* Methamphetamine)
d-METH (*see d*-Methamphetamine)
Methamphetamine (METH)
  AP-1 binding activities and, 13
  L-Arginine-NO pathway and, 178
  brain histaminergic neuron system and, 353
  GLT-1 immunoreactivity and, 310
  glutamate and, 315
  G protein subclass mRNAs and, 110
  human 14.3.3 η chain gene and, 64
  hypersensitivity of nucleus accumbens neurons to, 136
  nitric oxide and, 178
  nucleus accumbens and, 366
  poly-ADP-ribose polymerase and, 178
  serotonergic modulations and, 384
  striatal cAMP levels and, 378
d-Methamphetamine (*d*-METH), *d*-AMP neurotoxic properties in common with, 162
[^{11}C]Methamphetamine, 401
Methamphetamine psychosis
  behavioral sensitization and, 13
  plasma ME-LI and, 430
  spontaneous recurrence of, 415
Methionine enkephalin-like immunoreactivity (ME-LI), methamphetamine psychosis and, 431
N-Methyl-D-aspartate (NMDA) antagonists, METH-induced neurotoxicity and, 324
N-Methyl-D-aspartate (NMDA) receptor, non-aminergic effects of AMP on, 327
Methylenedioxyamphetamine (MDA), serotonin and, 168
d-Methylenedioxyamphetamine (*d*-MDA), *d*-AMP neurotoxic properties in common with, 162
3,4-Methylenedioxymethamphetamine (MDMA), serotonin and, 168
d-3,4-Methylenedioxymethamphetamine (*d*-MDMA), *d*-AMP neurotoxic properties in common with, 162
1-Methyl-4-phenylpyridinium (*see* MPP^+)
3-Methoxy-4-hydroxyphenylglycol (MHPG), plasma, 423
3-Methoxytyramine, striatal, 384

MHPG (*see* 3-Methoxy-4-hydroxy-phenylglycol)
Microiontophoretic application, 136
Monoamine concentrations, 394
Monoamine neurotransmitter function, 425
Morphine, ssCRE-BP and, 39
Morphogenesis, embryonic, 239
Morphometry, prefrontal cortex, 256
Motivation, gestational cocaine and, 303
MPP^+, dopamine transporter and, 391
MPP^+ toxicity, 391
mRNA, cocaine and, 92
mRNA, mGIRK, 101
MRS (*see* Magnetic resonance spectroscopy)
Mutagenesis, site-directed, 389
Mutant mice, dopamine D_1 receptor, 52

NAA (*see N*-Acetylaspartate)
L-NAME (*see* N^G-Nitro-L-arginine methyl ester)
NE-100, *p*-CA-induced neurotoxicity and, 200
NE-100, PCP-induced place aversion and, 33
Neural networks, 121
Neurodegeneration, ibogaine, 221
Neurodegeneration mechanisms, ibogaine, 237
Neurofilament-68, ibogaine and, 207
Neuronal functions, subacute PCP-induced changes in, 33
Neurotoxicity
  ibogaine and, 205
  methamphetamine-induced, 317
Neurotransmitters, 240
Nicotinamide-adenine dinucleotide phosphate (NADPH) diaphorase histochemistry, 230
Nicotine, psychotoxicity and, 367
Nitric oxide (NO)
  METH-induced toxicity and, 178
  NMDA receptor/ion channel complexes and, 31
Nitric oxide synthase (NOS) localization, 234
N^G-Nitro-L-arginine methyl ester (L-NAME), subacute PCP and, 31
NMDA (*see N*-Methyl-D-aspartate)
NO (*see* Nitric oxide)
Nonhuman primate animal model, gestational cocaine in, 301
Norepinephrine, plasma, 422
Northern blot analysis, G protein subclass mRNA expression measured by, 111
NOS (*see* Nitric oxide synthase)
Nucleus accumbens
  AP-1 binding activities in, 14
  dopamine D_1 receptor binding in, 295
  dopamine D_1 receptor mutant mice and, 56
  mesolimbic dopamine system and, 361
  methamphetamine and dopamine and, 136

Oligonucleotide, G protein subclasses and, 111
Opioid receptors, GIRK channels coexistent with, 104

PADPRP (*see* Poly-ADP-ribose polymerase)
Parkinsonism, 391
pCA (*see p*-Chloroamphetamine)
PCR mimic (*see* Polymerase chain reaction mimic)
Pharmacodynamics
  ibogaine, 227
  species differences and, 117
Pharmacokinetic change, behavioral sensitization and, 407
Pharmacokinetics, species differences and, 117
Phencyclidine (PCP), neuronal systems and, 29
4-Phenyl-4-(1-phenylbutyl)piperidine (*see* 4-PPBP)
Phorbol ester, PKC activated by, 336
Placenta, SERT and, 240
Poly-ADP-ribose polymerase (PADPRP), METH-induced toxicity and, 178
Polyamine, cocaine or lidocaine and, 344
Polymerase chain reaction (PCR) mimic, cocaine and, 90
Positron emission tomography (PET), [^{11}C]MAP and, 402
4-PPBP, pCA-induced neurotoxicity and, 200
Prefrontal cortex, growth parameters and morphometry of, 256
Prenatal cocaine, dopamine and, 289
Prenatal exposure
  amphetamine and, 256
  cocaine and, 256
Primary neuronal cell culture, 328
Protein kinase C (PKC), cocaine and, 88
Protein kinase C (PKC) inhibitors, 333
Psychopharmacology, ibogaine, 236
Psychotoxicity, AMP and cocaine and, 361
Putrescine, cocaine and, 346

Quantitative structure activity relationships (QSAR), 121

Radioimmunoassay (RIA), methamphetamine psychosis and, 431
Rat
  ibogaine and, 206
  retina of, 274
  striatum of, increased GLT-1 immunoreactivity in, 310
Reflexes at birth, gestational cocaine and, 305
Regulatory risk, ibogaine and, 218
Repeated administration of methamphetamine, 136
Restraint, *d*-AMP and, 153
Retina, vascular disruption in, 274
RIA (*see* Radioimmunoassay)
Risperidone, subacute PCP and, 31
Ritanserin, subacute PCP and, 31
Rolipram, striatal cAMP levels and, 378
[^{125}I]RTI-55, 247

SCH 23390
  AP-1 binding activity and, 15
  PCP-induced place aversion and, 33
Seizures, cocaine-induced, 340
Serotonergic modulations, 384
Serotonin (5-HT)
  dextromethorphan and, 201
  dopamine-increasing effect of METH and, 368
  methamphetamine and, 193
  PCP and, 29
Serotonin receptor subtypes, 384
Sigma receptor ligands, *p*-chloroamphetamine and, 199
Single-stranded cAMP-response element (ssCRE), morphine and, 39
Single-stranded cAMP response element binding protein (ssCRE-BP), mouse cerebellum, 41
Solvent abuse, proton MR spectroscopy and, 441
Species differences, pharmacokinetics and pharmacodynamics and, 116
Spermidine, cocaine and, 346
Spermine, cocaine or lidocaine and, 346
ssCRE (*see* Single-stranded cAMP response element)
ssCRE-BP (*see* Single-stranded cAMP response element binding protein)
Stress, *d*-AMP and, 148
Striatum, AP-1 binding activities in, 14
Substantia nigra, TH mRNA and, 374

[^{3}H] TCP intact cell binding, effect of AMP on, 329
Temperature, body, *d*-AMP and, 151
Temperature, environmental, METH-induced dopaminergic toxicity and, 187
TH (*see* Tyrosine hydroxylase)
[^{3}H]*N*-[1-(2-Thienyl)cyclohexyl]-piperidine (*see* [^{3}H]TCP)
Tolerance and dependence, ssCRE-BP involved in, 49
Transcription factor, ssCRE-BP as, 46
Tyrosine hydroxylase (TH)
  d-AMP and, 151
  METH and, 371
Tyrosine kinase inhibitors, 335

Vascular disruption, 274
Ventral tegmental area (VTA)
  methamphetamine and dopamine and, 136
  TH mRNA and, 374

White matter change, 441

Xenopus oocytes, mGIRK1 channel in, 104